A Novel Oral Natural Extract for the Treatment of Senile Purpura

NCT ID: NCT01183910

Last Updated: 2011-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, double-blind, placebo controlled study to assess the safety and effectiveness of a novel oral natural extract to improve the appearance of the skin of patients with senile purpura.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PURPURA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Calcium carbonate placebo pill

Placebo medication to treat the appearance of the skin in patients with senile purpura

Group Type PLACEBO_COMPARATOR

Calcium Carbonate

Intervention Type DIETARY_SUPPLEMENT

Oral Tablet Taken Twice a Day

Nutraceutical

Patients take a novel, natural nutraceutical product to improve the appearance of the skin of patients with senile purpura

Group Type ACTIVE_COMPARATOR

Citrus Bioflavanoid Blend

Intervention Type DIETARY_SUPPLEMENT

Pill Taken Twice a Day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Citrus Bioflavanoid Blend

Pill Taken Twice a Day

Intervention Type DIETARY_SUPPLEMENT

Calcium Carbonate

Oral Tablet Taken Twice a Day

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with evidence of purpura on physical exam

Exclusion Criteria

* Preexisting condition that would not allow the patients to take oral calcium supplement
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nexgen Dermatologics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

NEXGEN DERMATOLOGICS, INC.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

JOSHUA M BERLIN, MD

Role: PRINCIPAL_INVESTIGATOR

STUDY PROTOCOL, INC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Berlin Center of Medical Aesthetics

Boynton Beach, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

021775

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study to Evaluate the Safety of Colchicine
NCT05335148 RECRUITING PHASE1
Calcinosis Reduction by Pyrophosphate in SSC
NCT04966416 NOT_YET_RECRUITING NA
ST266 in UV-induced Inflammation
NCT02389777 COMPLETED PHASE2